术前CALLY指数、SII水平对肝细胞肝癌手术切除的预后评估价值
Prognostic Value of Preoperative CALLY Index and SII Level in Hepatocellular Carcinoma Resection
摘要: 目的:探讨术前C-反应蛋白–白蛋白–淋巴细胞指数(C-reactive protein-albumin-lymphocyte index, CALLY index)、系统免疫炎症指数(systemic immune-inflammation index, SII)评估肝细胞肝癌(hepatocellular carcinoma, HCC)患者术后预后的价值。方法:回顾性分析2018年1月~2020年12月于青岛大学附属医院初次行根治性手术治疗的94例HCC患者,依据手术前1周内最近一次化验结果计算出CALLY指数和SII,利用受试者工作曲线(receiver operating characteristic curve,ROC曲线)确定术前CALLY指数和SII的最佳临界值,并根据最佳临界值把病人分为高CALLY指数组和低CALLY指数组、高SII组和低SII组,使用χ2检验分析不同组别HCC患者基本资料的差异,使用Kaplan-Meier法和Log-Rank检验绘制并检验不同组别患者的生存曲线,使用Cox回归比例风险模型进行单因素和多因素的分析。结果:通过ROC曲线计算出术前CALLY指数的最佳临界值为3.90,将病人分为低CALLY指数水平组(<3.90,47例)和CALLY指数高水平组(≥3.90,47例);术前SII的最佳临界值为492.31,将病人分为低SII水平组(<492.31,75例)和高SII水平组(≥492.31,19例)。与高CALLY指数水平组相比,低水平组的肿瘤直径较大、TNM分期更晚(P < 0.05),与低SII水平组相比,高水平组的患者年纪更大、肿瘤直径较大(P < 0.05)。单因素结果分析显示,CALLY指数、SII、是否复发与HCC患者的预后有关(P < 0.05)。多因素分析结果显示,CALLY指数水平是影响肝癌预后的独立危险因素(P < 0.05)。结论:CALLY指数低水平是影响HCC患者预后的独立风险因素。术前CALLY指数高水平表明肝细胞肝癌TNM分期处在更早期,肿瘤直径更小;术前SII低水平表明肝细胞肝癌肿瘤直径更小。术前CALLY指数高水平、SII低水平HCC患者的生存时间更长。
Abstract: Objective: To investigate the value of preoperative C-reactive protein-albumin-lymphocyte index (CALLY index), systemic immune-inflammation index (SII) in assessing the prognosis of patients with hepatocellular carcinoma (HCC). Methods: Retrospective analysis of 94 HCC patients who un-derwent radical surgery for the first time in the Affiliated Hospital of Qingdao University from Janu-ary 2018 to December 2020, CALLY index and SII were calculated based on the results of the most recent blood test within 1 week before surgery, and the optimal critical values of preoperative CALLY index and SII were determined by using the receiver operating characteristic (ROC) curve. The ROC curve was used to determine the optimal preoperative thresholds of CALLY index and SII, and patients were divided into high CALLY index and low CALLY index groups, and high SII and low SII groups according to the recent thresholds, and differences in the basic data of HCC patients in different groups were analysed using the χ2 test, and differences in the basic data of HCC patients in different groups were plotted and tested using the Kaplan-Meier method and the Log- Rank test. Survival curves of patients in different groups were analysed using Cox regression proportional risk model for univariate and multivariate analyses. Results: The optimal critical value of preoperative CALLY index was calculated as 3.90 by ROC curve, and patients were divided into low CALLY index level group (<3.90, 47 cases) and high CALLY index level group (≥3.90, 47 cases); the optimal criti-cal value of preoperative SII was 492.31, and patients were divided into low SII level group (<492.31, 75 cases) and high SII level group (≥492.31, 19 cases). The low level group had larger tumour diameters and later TNM staging compared to the high CALLY index level group (P < 0.05), and patients in the high level group were older and had larger tumour diameters compared to the low SII level group (P < 0.05). Univariate analysis of the results showed that CALLY index, SII, and the presence of recurrence were associated with the prognosis of HCC patients (P < 0.05). Multifac-torial analysis of the results showed that the level of CALLY index was an independent risk factor affecting the prognosis of hepatocellular carcinoma (P < 0.05). Conclusion: The low level of CALLY index is an independent risk factor affecting the prognosis of HCC patients. A high preoperative CALLY index indicates that the TNM stage of hepatocellular carcinoma is earlier and the tumor di-ameter is smaller. Low preoperative SII levels indicate that hepatocellular carcinoma tumors are smaller in diameter. The survival time of HCC patients with high preoperative CALLY index and low preoperative SII was longer.
文章引用:张浩文, 郭卫东. 术前CALLY指数、SII水平对肝细胞肝癌手术切除的预后评估价值[J]. 临床医学进展, 2024, 14(1): 1958-1969. https://doi.org/10.12677/ACM.2024.141276

参考文献

[1] Siegel, R.L., Miller, K.D., Fuchs, H.E., et al. (2022) Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72, 7-33. [Google Scholar] [CrossRef] [PubMed]
[2] Gao, S., Chen, T., Li, L., et al. (2020) Hypoxia-Inducible Ubiquitin Specific Peptidase 13 Contributes to Tumor Growth and Metastasis via Enhancing the Toll-Like Receptor 4/Myeloid Differentiation Primary Response Gene 88/Nuclear Factor-κB Pathway in Hepatocellular Carcinoma. Frontiers in Cell and Developmental Biology, 8, Article 587389. [Google Scholar] [CrossRef] [PubMed]
[3] Cheung, T.T., Dai, W.C., Tsang, S.H., et al. (2016) Pure Laparoscopic Hepatectomy versus Open Hepatectomy for Hepatocellular Carcino-ma in 110 Patients with Liver Cirrhosis: A Propensity Analysis at a Single Center. Annals of Surgery, 264, 612-620. [Google Scholar] [CrossRef
[4] Belli, G., Limongelli, P., Fantini, C., et al. (2009) Laparo-scopic and Open Treatment of Hepatocellular Carcinoma in Patients with Cirrhosis. British Journal of Surgery, 96, 1041-1048. [Google Scholar] [CrossRef] [PubMed]
[5] 马逸云, 蒋华, 张宏亨. 腹腔镜肝切除术与开腹肝切除术治疗肝硬化肝细胞癌患者的效果比较[J]. 临床肝胆病杂志, 2016, 32(10): 1916-1919.
[6] Memeo, R., De’Angelis, N., Compagnon, P., et al. (2014) Laparoscopic vs. Open Liver Resection for Hepatocellular Carcinoma of Cirrhotic Liver: A Case-Control Study. World Journal of Surgery, 38, 2919-2926. [Google Scholar] [CrossRef] [PubMed]
[7] Cupp, M.A., Cariolou, M., Tzoulaki, I., et al. (2020) Neutrophil to Lymphocyte Ratio and Cancer Prognosis: An Umbrella Review of Systematic Reviews and Meta-Analyses of Observa-tional Studies. BMC Medicine, 18, Article No. 360. [Google Scholar] [CrossRef] [PubMed]
[8] 王明弘, 江斌, 王健, 等. 系统免疫炎症指数与肝细胞癌切除术后预后相关性分析[J]. 腹部外科, 2022, 35(1): 31-36, 46.
[9] Muller, L., Hahn, F., Mahringer-Kunz, A., et al. (2021) Immunonutritive Scoring for Patients with Hepatocel-lular Carcinoma Undergoing Transarterial Chemoembolization: Evaluation of the CALLY Index. Cancers, 13, Article 5018. [Google Scholar] [CrossRef] [PubMed]
[10] Balkwill, F. and Mantovani, A. (2001) Inflammation and Cancer: Back to Virchow? Lancet, 357, 539-545. [Google Scholar] [CrossRef
[11] Hanahan, D. (2022) Hallmarks of Cancer: New Dimensions. Cancer Discovery, 12, 31-46. [Google Scholar] [CrossRef
[12] Ocana, A., Nieto-Jimenez, C., Pandiella, A., et al. (2017) Neutrophils in Cancer: Prognostic Role and Therapeutic Strategies. Molecular Cancer, 16, Article No. 137. [Google Scholar] [CrossRef] [PubMed]
[13] Coffelt, S.B., Wellenstein, M.D. and De Visser, K.E. (2016) Neu-trophils in Cancer: Neutral No More. Nature Reviews Cancer, 16, 431-446. [Google Scholar] [CrossRef] [PubMed]
[14] Jaillon, S., Ponzetta, A., Di Mitri, D., et al. (2020) Neutrophil Diversity and Plasticity in Tumour Progression and Therapy. Nature Reviews Cancer, 20, 485-503. [Google Scholar] [CrossRef] [PubMed]
[15] Gao, L., Zhang, H., Zhang, B., et al. (2017) Prognostic Value of Combination of Preoperative Platelet Count and Mean Platelet Volume in Patients with Resectable Non-Small Cell Lung Cancer. Oncotarget, 8, 15632-15641. [Google Scholar] [CrossRef] [PubMed]
[16] Palacios-Acedo, A.L., Langiu, M., Crescence, L., et al. (2022) Platelet and Cancer-Cell Interactions Modulate Cancer-Associated Thrombosis Risk in Different Cancer Types. Cancers, 14, Article 730. [Google Scholar] [CrossRef] [PubMed]
[17] Wang, Y., Yang, X., Yu, Y., et al. (2018) Immunotherapy of Patient with Hepatocellular Carcinoma Using Cytotoxic T Lymphocytes ex Vivo Activated with Tumor Antigen-Pulsed Dendritic Cells. Journal of Cancer, 9, 275-287. [Google Scholar] [CrossRef] [PubMed]
[18] Hu, B., Yang, X.R., Xu, Y., et al. (2014) Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 20, 6212-6222. [Google Scholar] [CrossRef
[19] 刘霄, 唐菁, 李笃军. C-反应蛋白在肿瘤发生发展中的作用[J]. 生命的化学, 2011, 31(6): 868-870.
[20] Gupta, D. and Lis, C.G. (2010) Pretreatment Serum Albumin as a Predictor of Cancer Survival: A Systematic Review of the Epidemiological Literature. Nutrition Journal, 9, Article No. 69. [Google Scholar] [CrossRef] [PubMed]
[21] Iida, H., Tani, M., Komeda, K., et al. (2022) Superiority of CRP-Albumin-Lymphocyte Index (CALLY Index) as a Non-Invasive Prognostic Biomarker after Hepatectomy for Hepatocellular Carcinoma. HPB, 24, 101-115. [Google Scholar] [CrossRef] [PubMed]
[22] Wang, W., Gu, J., Liu, Y., et al. (2022) Pre-Treatment CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker of Survival in Patients with Epithelial Ovarian Cancer. Cancer Management and Research, 14, 2803-2812. [Google Scholar] [CrossRef
[23] Tsai, Y.T., Ko, C.A., Chen, H.C., et al. (2022) Prognostic Value of CRP-Albumin-Lymphocyte (CALLY) Index in Patients Undergoing Surgery for Oral Cavity Cancer. Journal of Cancer, 13, 3000-3012. [Google Scholar] [CrossRef] [PubMed]
[24] Liu, X.Y., Zhang, X., Zhang, Q., et al. (2023) The Value of CRP-Albumin-Lymphocyte Index (CALLY Index) as a Prognostic Biomarker in Patients with Non-Small Cell Lung Cancer. Support Care Cancer, 31, Article No. 533. [Google Scholar] [CrossRef] [PubMed]
[25] Yang, M., Lin, S.Q., Liu, X.Y., et al. (2023) Association be-tween C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index and Overall Survival in Patients with Colorectal Cancer: From the Investigation on Nutrition Status and Clinical Outcome of Common Cancers Study. Frontiers in Immunology, 14, Article ID: 1131496. [Google Scholar] [CrossRef] [PubMed]